These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 27067333

  • 21. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
    Cabrera SE, Santos D, Valverde MP, Domínguez-Gil A, González F, Luna G, García MJ.
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2791-8. PubMed ID: 19433561
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.
    Abdelhady AM, Desta Z, Jiang F, Yeo CW, Shin JG, Overholser BR.
    J Clin Pharmacol; 2014 Jan; 54(1):87-96. PubMed ID: 24142869
    [Abstract] [Full Text] [Related]

  • 24. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH.
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [Abstract] [Full Text] [Related]

  • 25. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
    Aouri M, Barcelo C, Ternon B, Cavassini M, Anagnostopoulos A, Yerly S, Hugues H, Vernazza P, Günthard HF, Buclin T, Telenti A, Rotger M, Decosterd LA, Swiss HIV Cohort Study.
    Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
    Gupta SK, Rosenkranz SL, Cramer YS, Koletar SL, Szczech LA, Amorosa V, Hall SD.
    AIDS; 2008 Oct 01; 22(15):1919-27. PubMed ID: 18784455
    [Abstract] [Full Text] [Related]

  • 30. Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults.
    Meng XM, Li ZR, Zheng XY, Liu YX, Niu WJ, Qiu XY, Lu HZ.
    Eur J Pharm Sci; 2021 Dec 01; 167():105986. PubMed ID: 34474119
    [Abstract] [Full Text] [Related]

  • 31. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
    Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH.
    AIDS; 2009 Oct 23; 23(16):2101-6. PubMed ID: 19779319
    [Abstract] [Full Text] [Related]

  • 32. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
    Alghamdi WA, Antwi S, Enimil A, Yang H, Dompreh A, Wiesner L, Langaee T, Peloquin CA, Kwara A.
    J Antimicrob Chemother; 2019 Sep 01; 74(9):2698-2706. PubMed ID: 31243456
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    Ramachandran G, Kumar AK, Ponnuraja C, Ramesh K, Rajesh L, Chandrasekharan C, Swaminathan S.
    Indian J Med Res; 2013 Dec 01; 138(6):955-61. PubMed ID: 24521642
    [Abstract] [Full Text] [Related]

  • 35. Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
    Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay M, Moorthy GS, Ratshaa BR, Han X, Steenhoff AP, Mosepele M, Strom BL, Aplenc R, Bisson GP, Gross R.
    J Acquir Immune Defic Syndr; 2017 Aug 01; 75(4):488-491. PubMed ID: 28481785
    [Abstract] [Full Text] [Related]

  • 36. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P, Masimirembwa C.
    BMC Pharmacol Toxicol; 2015 Mar 27; 16():4. PubMed ID: 25889207
    [Abstract] [Full Text] [Related]

  • 37. Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?
    Liu J, Chan-Tack KM, Jadhav P, Seo S, Robertson SM, Kraft J, Singer ME, Struble KA, Arya V.
    Int J Clin Pharmacol Ther; 2014 Jun 27; 52(6):446-53. PubMed ID: 24755134
    [Abstract] [Full Text] [Related]

  • 38. Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
    Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN.
    Drug Metab Dispos; 2013 Feb 27; 41(2):422-9. PubMed ID: 23166317
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
    Leger P, Dillingham R, Beauharnais CA, Kashuba AD, Rezk NL, Fitzgerald DW, Pape JW, Haas DW.
    J Infect Dis; 2009 Sep 15; 200(6):955-64. PubMed ID: 19659438
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.